EUCTR2010-019373-15-DE进行中（未招募）不适用
A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions in patients with type-I allergy
Marinomed Biotechnologie GmbH0 个研究点目标入组 40 人开始时间: 2010年4月23日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •men and women aged 18 – 64 years with a proven typ-I allergy against the corresponding allergen (grass pollen, tree pollen [birch, alder, hazel] or cat epithelia);
- •the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical trial;
- •female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner;
- •written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •acne, suntan, eczema, hyperpigmentation or tattoos in the test fields;
- •dark-skinned persons whose skin color prevents ready assessment of skin reactions;
- •acute allergic symptoms;
- •known allergy to parabens;
- •with anamestics indication for anaphylaxis or bronchial asthma wich is not well adjusted (FEV < 70%);
- •dermographism;
- •evidence of drug or alcohol abuse;
- •pregnancy or nursing;
- •planned surgical procedure within the time frame of the trial;
- •symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks before and during the trial;
- •participation in the treatment phase of another clinical trial within the last four weeks prior to the first administration of investigational product in this clinical trial;
- •treatment with systemic or locally acting medications which might counter or influence the trial aim within four weeks before the baseline visit and during the trial (e.g. antihistamines or glucocorticosteroids);
- •contraindications according to summary of product characteristics:
- •o known hypersensitivity against one of the components (for Flogencylâ: ß-aescin, for FenistilÒ Gel: Dimethindene maleate, and for AdvantanÒ Creme: Methylprednisolone aceponate);
- •o specific skin process or skin diseases (e.g. skin tuberculosis, herpes, varicella) (for AdvantanCreme);
- •o skin reactions after vaccination (for AdvantanÒ Creme);
- •in the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical trial, e.g. due to probable noncompliance or inability to understand the trial and give adequately informed consent;
- •subject is institutionalized because of legal or regulatory order.
研究者
相似试验
进行中（未招募）
1 期
A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in an expanded flora test with healthy subjects - Marples KligmaEUCTR2009-009948-23-DEAlmirall Hermal GmbH20
进行中（未招募）
不适用
A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in anexpanded flora test with healthy subjects - Marples Kligman TestHealthy volunteer trial to investigate whether topical formulations containing Octenidine and Octenidine plus Prednicarbate exert an in vivo antibacterial action on skin surface bacteria multiplied by occlusion using the expanded flora test”EUCTR2008-003362-26-DEAlmirall Hermal GmbH
进行中（未招募）
不适用
A phase II, single-center, randomized, controlled, observer-blind study to determine the non-inferiority of a topical mometasone formulation vs a marketed comparator by evaluation of the anti-psoriatic efficacy in a psoriasis plaque testEUCTR2008-002141-24-DEAlmirall Hermal GmbH
进行中（未招募）
不适用
A phase II, single-center, randomized, controlled, observer-blind study with intra-individual comparisons within two parallel groups to assess the efficacy of a topical Aescin formulation in the treatment of allergic contact dermatitissubjects with proven nickel allergyEUCTR2009-009379-36-DEMarinomed Biotechnologie GmbH40
进行中（未招募）
不适用
A phase II, single-center, randomized, controlled, double-blind study to assess effects on skin conditions and patient reported outcome of a topical formulation containing LAS41002 on lesional skin in patients with atopic eczema - ADClinical condition of atopic eczema mild to moderate defined by a local SCORAD of at least 5 with •erythma = 2•lichenification = 1•dryness = 1 •itching = 1•Erlangen atopy score sum equal or higher than 10 pointsMedDRA version: 12.1Level: LLTClassification code 10003639Term: Atopic dermatitisEUCTR2009-017407-28-DEAlmirall Hermal GmbH